tiprankstipranks
Trending News
More News >
Apellis Pharmaceuticals Inc (APLS)
NASDAQ:APLS
US Market

Apellis Pharmaceuticals (APLS) Stock Forecast & Price Target

Compare
894 Followers
See the Price Targets and Ratings of:

APLS Analyst Ratings

Moderate Buy
19Ratings
Moderate Buy
11 Buy
8 Hold
0 Sell
Based on 19 analysts giving stock ratings to
Apellis
Pharmaceuticals
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

APLS Stock 12 Month Forecast

Average Price Target

$35.47
▲(91.63%Upside)
Based on 19 Wall Street analysts offering 12 month price targets for Apellis Pharmaceuticals in the last 3 months. The average price target is $35.47 with a high forecast of $57.00 and a low forecast of $18.00. The average price target represents a 91.63% change from the last price of $18.51.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"17":"$17","58":"$58","27.25":"$27.3","37.5":"$37.5","47.75":"$47.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":57,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$57.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":35.47,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$35.47</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":18,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$18.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[17,27.25,37.5,47.75,58],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2024","6":"Dec<br/>2024","9":"Mar<br/>2025","12":"Jun<br/>2025","25":"Jun<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,19.14,22.052307692307693,24.964615384615385,27.876923076923077,30.78923076923077,33.70153846153846,36.613846153846154,39.526153846153846,42.43846153846154,45.35076923076923,48.26307692307692,51.175384615384615,54.08769230769231,{"y":57,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,19.14,20.396153846153847,21.652307692307694,22.908461538461538,24.164615384615384,25.42076923076923,26.676923076923075,27.93307692307692,29.189230769230768,30.445384615384615,31.701538461538462,32.957692307692305,34.21384615384615,{"y":35.47,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,19.14,19.052307692307693,18.964615384615385,18.876923076923077,18.78923076923077,18.701538461538462,18.613846153846154,18.526153846153846,18.43846153846154,18.35076923076923,18.263076923076923,18.175384615384615,18.087692307692308,{"y":18,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":39.25,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.29,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":38.9,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.74,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.98,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 24, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.42,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.91,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.01,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.15,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.68,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.08,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.14,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$57.00Average Price Target$35.47Lowest Price Target$18.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TipRanks Analyst forecast on APLS
TipRanks AITipRanks
Not Ranked
TipRanks
$19.5
Hold
5.35%
Upside
Reiterated
06/03/25
Apellis Pharmaceuticals' stock score reflects strong revenue growth and strategic FDA milestones tempered by ongoing profitability challenges and negative market momentum. The stock's valuation is affected by its negative earnings, and while corporate governance improvements are positive, they do not significantly alter the current financial outlook.
Wells Fargo Analyst forecast on APLS
Derek ArchilaWells Fargo
Wells Fargo
$26$29
Hold
56.67%
Upside
Reiterated
06/02/25
Cautious Hold on Apellis Pharmaceuticals Amid Uncertainties with Pegcetacoplan Launch and Financial Stability
Piper Sandler Analyst forecast on APLS
Biren AminPiper Sandler
Piper Sandler
$26
Hold
40.46%
Upside
Reiterated
05/28/25
Piper Sandler Remains a Hold on Apellis Pharmaceuticals (APLS)
Citi
$49$41
Buy
121.50%
Upside
Reiterated
05/22/25
Apellis Pharmaceuticals (APLS) PT Lowered to $41 at Citi, Opens 90-Day Upside Catalyst WatchCiti analyst Yigal Nochomovitz lowered the price target on Apellis Pharmaceuticals (NASDAQ: APLS) to $41.00 (from $49.00) while maintaining a Buy rating.
J.P. Morgan Analyst forecast on APLS
Anupam RamaJ.P. Morgan
J.P. Morgan
$45$35
Buy
89.09%
Upside
Reiterated
05/22/25
Analysts Are Bullish on These Healthcare Stocks: Lineage Therap (LCTX), Apellis Pharmaceuticals (APLS)
Bank of America Securities Analyst forecast on APLS
Tazeen AhmadBank of America Securities
Bank of America Securities
$23
Hold
24.26%
Upside
Reiterated
05/14/25
Bank of America Securities Sticks to Their Hold Rating for Apellis Pharmaceuticals (APLS)
Mizuho Securities Analyst forecast on APLS
Graig SuvannavejhMizuho Securities
Mizuho Securities
$30$20
Hold
8.05%
Upside
Reiterated
05/14/25
Analysts Offer Insights on Healthcare Companies: Editas Medicine (NASDAQ: EDIT), Apellis Pharmaceuticals (NASDAQ: APLS) and Argenx Se (NASDAQ: ARGX)
Cantor Fitzgerald Analyst forecast on APLS
Steven SeedhouseCantor Fitzgerald
Cantor Fitzgerald
$75$52
Buy
180.93%
Upside
Reiterated
05/09/25
Raymond James downgrades Apellis Pharmaceuticals (APLS) to Outperform
Raymond James Analyst forecast on APLS
Ryan DeschnerRaymond James
Raymond James
$52
Buy
180.93%
Upside
Downgraded
05/09/25
Apellis downgraded to Outperform from Strong Buy at Raymond JamesApellis downgraded to Outperform from Strong Buy at Raymond James
H.C. Wainwright Analyst forecast on APLS
Douglas TsaoH.C. Wainwright
H.C. Wainwright
$57
Buy
207.94%
Upside
Reiterated
05/08/25
Optimistic Growth Potential for Apellis Pharmaceuticals Despite Temporary Setbacks
Scotiabank Analyst forecast on APLS
Greg HarrisonScotiabank
Scotiabank
$31$20
Hold
8.05%
Upside
Reiterated
05/08/25
Scotiabank Keeps Their Hold Rating on Apellis Pharmaceuticals (APLS)
Morgan Stanley Analyst forecast on APLS
Judah FrommerMorgan Stanley
Morgan Stanley
$30$25
Hold
35.06%
Upside
Reiterated
05/08/25
Apellis Pharmaceuticals (APLS) PT Lowered to $25 at Morgan StanleyMorgan Stanley analyst Judah Frommer lowered the price target on Apellis Pharmaceuticals (NASDAQ: APLS) to $25.00 (from $30.00) while maintaining a Equalweight rating.
Robert W. Baird Analyst forecast on APLS
Colleen M. KusyRobert W. Baird
Robert W. Baird
$55$47
Buy
153.92%
Upside
Reiterated
05/08/25
Apellis price target lowered to $47 from $55 at BairdApellis price target lowered to $47 from $55 at Baird
TD Cowen Analyst forecast on APLS
Phil NadeauTD Cowen
TD Cowen
$60$50
Buy
170.12%
Upside
Reiterated
05/07/25
Apellis Pharmaceuticals: Buy Rating Reaffirmed Amid Growth Potential and Market Leadership in GA
William Blair
Buy
Reiterated
05/07/25
Apellis Pharmaceuticals: Long-term Growth Potential and Market Recovery Underpin Buy Rating
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TipRanks Analyst forecast on APLS
TipRanks AITipRanks
Not Ranked
TipRanks
$19.5
Hold
5.35%
Upside
Reiterated
06/03/25
Apellis Pharmaceuticals' stock score reflects strong revenue growth and strategic FDA milestones tempered by ongoing profitability challenges and negative market momentum. The stock's valuation is affected by its negative earnings, and while corporate governance improvements are positive, they do not significantly alter the current financial outlook.
Wells Fargo Analyst forecast on APLS
Derek ArchilaWells Fargo
Wells Fargo
$26$29
Hold
56.67%
Upside
Reiterated
06/02/25
Cautious Hold on Apellis Pharmaceuticals Amid Uncertainties with Pegcetacoplan Launch and Financial Stability
Piper Sandler Analyst forecast on APLS
Biren AminPiper Sandler
Piper Sandler
$26
Hold
40.46%
Upside
Reiterated
05/28/25
Piper Sandler Remains a Hold on Apellis Pharmaceuticals (APLS)
Citi
$49$41
Buy
121.50%
Upside
Reiterated
05/22/25
Apellis Pharmaceuticals (APLS) PT Lowered to $41 at Citi, Opens 90-Day Upside Catalyst WatchCiti analyst Yigal Nochomovitz lowered the price target on Apellis Pharmaceuticals (NASDAQ: APLS) to $41.00 (from $49.00) while maintaining a Buy rating.
J.P. Morgan Analyst forecast on APLS
Anupam RamaJ.P. Morgan
J.P. Morgan
$45$35
Buy
89.09%
Upside
Reiterated
05/22/25
Analysts Are Bullish on These Healthcare Stocks: Lineage Therap (LCTX), Apellis Pharmaceuticals (APLS)
Bank of America Securities Analyst forecast on APLS
Tazeen AhmadBank of America Securities
Bank of America Securities
$23
Hold
24.26%
Upside
Reiterated
05/14/25
Bank of America Securities Sticks to Their Hold Rating for Apellis Pharmaceuticals (APLS)
Mizuho Securities Analyst forecast on APLS
Graig SuvannavejhMizuho Securities
Mizuho Securities
$30$20
Hold
8.05%
Upside
Reiterated
05/14/25
Analysts Offer Insights on Healthcare Companies: Editas Medicine (NASDAQ: EDIT), Apellis Pharmaceuticals (NASDAQ: APLS) and Argenx Se (NASDAQ: ARGX)
Cantor Fitzgerald Analyst forecast on APLS
Steven SeedhouseCantor Fitzgerald
Cantor Fitzgerald
$75$52
Buy
180.93%
Upside
Reiterated
05/09/25
Raymond James downgrades Apellis Pharmaceuticals (APLS) to Outperform
Raymond James Analyst forecast on APLS
Ryan DeschnerRaymond James
Raymond James
$52
Buy
180.93%
Upside
Downgraded
05/09/25
Apellis downgraded to Outperform from Strong Buy at Raymond JamesApellis downgraded to Outperform from Strong Buy at Raymond James
H.C. Wainwright Analyst forecast on APLS
Douglas TsaoH.C. Wainwright
H.C. Wainwright
$57
Buy
207.94%
Upside
Reiterated
05/08/25
Optimistic Growth Potential for Apellis Pharmaceuticals Despite Temporary Setbacks
Scotiabank Analyst forecast on APLS
Greg HarrisonScotiabank
Scotiabank
$31$20
Hold
8.05%
Upside
Reiterated
05/08/25
Scotiabank Keeps Their Hold Rating on Apellis Pharmaceuticals (APLS)
Morgan Stanley Analyst forecast on APLS
Judah FrommerMorgan Stanley
Morgan Stanley
$30$25
Hold
35.06%
Upside
Reiterated
05/08/25
Apellis Pharmaceuticals (APLS) PT Lowered to $25 at Morgan StanleyMorgan Stanley analyst Judah Frommer lowered the price target on Apellis Pharmaceuticals (NASDAQ: APLS) to $25.00 (from $30.00) while maintaining a Equalweight rating.
Robert W. Baird Analyst forecast on APLS
Colleen M. KusyRobert W. Baird
Robert W. Baird
$55$47
Buy
153.92%
Upside
Reiterated
05/08/25
Apellis price target lowered to $47 from $55 at BairdApellis price target lowered to $47 from $55 at Baird
TD Cowen Analyst forecast on APLS
Phil NadeauTD Cowen
TD Cowen
$60$50
Buy
170.12%
Upside
Reiterated
05/07/25
Apellis Pharmaceuticals: Buy Rating Reaffirmed Amid Growth Potential and Market Leadership in GA
William Blair
Buy
Reiterated
05/07/25
Apellis Pharmaceuticals: Long-term Growth Potential and Market Recovery Underpin Buy Rating
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Apellis Pharmaceuticals

1 Month
xxx
Success Rate
18/28 ratings generated profit
64%
Average Return
+4.04%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 64.29% of your transactions generating a profit, with an average return of +4.04% per trade.
3 Months
xxx
Success Rate
17/27 ratings generated profit
63%
Average Return
+3.41%
reiterated a xxx
rating 29 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 62.96% of your transactions generating a profit, with an average return of +3.41% per trade.
1 Year
Success Rate
14/30 ratings generated profit
47%
Average Return
+1.67%
reiterated a buy rating 16 days ago
Copying Yigal Nochomovitz's trades and holding each position for 1 Year would result in 46.67% of your transactions generating a profit, with an average return of +1.67% per trade.
2 Years
xxx
Success Rate
14/27 ratings generated profit
52%
Average Return
-2.38%
reiterated a xxx
rating 29 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 51.85% of your transactions generating a profit, with an average return of -2.38% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

APLS Analyst Recommendation Trends

Rating
Feb 25
Mar 25
Apr 25
May 25
Jun 25
Strong Buy
13
20
18
17
10
Buy
4
5
5
6
4
Hold
18
23
22
23
18
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
35
48
45
46
32
In the current month, APLS has received 14 Buy Ratings, 18 Hold Ratings, and 0 Sell Ratings. APLS average Analyst price target in the past 3 months is 35.47.
Each month's total comprises the sum of three months' worth of ratings.

APLS Financial Forecast

APLS Earnings Forecast

Next quarter’s earnings estimate for APLS is -$0.47 with a range of -$0.75 to -$0.27. The previous quarter’s EPS was -$0.74. APLS beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.04% of the time in the same period. In the last calendar year APLS has Outperformed its overall industry.
Next quarter’s earnings estimate for APLS is -$0.47 with a range of -$0.75 to -$0.27. The previous quarter’s EPS was -$0.74. APLS beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.04% of the time in the same period. In the last calendar year APLS has Outperformed its overall industry.

APLS Sales Forecast

Next quarter’s sales forecast for APLS is $187.96M with a range of $167.18M to $217.40M. The previous quarter’s sales results were $166.80M. APLS beat its sales estimates 50.00% of the time in past 12 months, while its overall industry beat sales estimates 47.51% of the time in the same period. In the last calendar year APLS has Outperformed its overall industry.
Next quarter’s sales forecast for APLS is $187.96M with a range of $167.18M to $217.40M. The previous quarter’s sales results were $166.80M. APLS beat its sales estimates 50.00% of the time in past 12 months, while its overall industry beat sales estimates 47.51% of the time in the same period. In the last calendar year APLS has Outperformed its overall industry.

APLS Stock Forecast FAQ

What is APLS’s average 12-month price target, according to analysts?
Based on analyst ratings, Apellis Pharmaceuticals Inc’s 12-month average price target is 35.47.
    What is APLS’s upside potential, based on the analysts’ average price target?
    Apellis Pharmaceuticals Inc has 91.63% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is APLS a Buy, Sell or Hold?
          Apellis Pharmaceuticals Inc has a consensus rating of Moderate Buy which is based on 11 buy ratings, 8 hold ratings and 0 sell ratings.
            What is Apellis Pharmaceuticals Inc’s price target?
            The average price target for Apellis Pharmaceuticals Inc is 35.47. This is based on 19 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $57.00 ,the lowest forecast is $18.00. The average price target represents 91.63% Increase from the current price of $18.51.
              What do analysts say about Apellis Pharmaceuticals Inc?
              Apellis Pharmaceuticals Inc’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 19 Wall Streets Analysts.
                How can I buy shares of APLS?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis